Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in neoadjuvant locally advanced cervical cancer
NCT04238988Phase 2Unknown
- Sponsor
- Policlinico Gemelli
- Start
- Feb 2021
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in Cervical Cancer (CC), sponsored by Policlinico Gemelli. Primary endpoint: 2-years Progression-free survival at 42 months. Status: unknown.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04238988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04238988.